Clinical Trial

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR) high risk locally advanced rectal cancer.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2030-07 -> 2030-10 2026-07-29
minor Completion pushed: 2030-07 -> 2030-10 2026-07-29
Trial Details
NCT Number NCT07580339
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: DynamiCure Biotechnology
Conditions Rectal Cancer
Enrollment 30 participants
Start Date 2026-10
Primary Completion 2030-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-28